Headquartered in Morrisville, NC Fiscal year ends December NASDAQ: LQDA liquidia.com
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with challenging respiratory and vascular diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's flagship product is YUTREPIA (treprostinil) inhalation powder, an inhaled dry-powder formulation of treprostinil delivered through a palm-sized device, approved by the FDA for the treatment of PAH and PH-ILD. YUTREPIA was developed using Liquidia's proprietary PRINT technology, which enables the creation of drug particles that are precise and uniform in size, shape, and composition for enhanced lung deposition. The company is also developing L606, an investigational extended-release liposomal treprostinil inhalation suspension administered twice daily via a next-generation nebulizer, currently in Phase 3 studies. Additionally, Liquidia promotes generic Treprostinil Injection for PAH in the United States through a partnership with Sandoz. The company has 10 clinical studies ongoing or planned across known and new indications including PH-COPD, IPF/PPF, and systemic sclerosis-associated Raynaud's phenomenon. Updated
Liquidia reports at 6:30 AM ET, the first full look at YUTREPIA's launch economics while the United Therapeutics patent suit still hangs over it. Script ramp and cash burn decide whether the $7.8 billion market cap is already pricing the win.
A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled.
Friday's top analyst upgrades and downgrades included Barrick Gold, DraftKings, Hyatt Hotels, Nikola, Occidental Petroleum, Penn National Gaming, Shopify, T-Mobile, Uber, Valero Energy and Workday.
A new research report outlines favorable Liquidia Technologies drug study data that will be presented in the coming weeks, which could add up to more than 300% potential upside.
Jon C. Ogg Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with challenging respiratory and vascular diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The Wall Street consensus 12-month price target for LQDA is $49.33.
